(Q37641052)

21 August 2017

1 reference

title

Clinical relevance of FGF-23 in chronic kidney disease (English)

1 reference

21 August 2017

Sarah Seiler

1

1 reference

PubMed ID

19946326

21 August 2017

Gunnar H Heine

series ordinal

2

1 reference

PubMed ID

19946326

21 August 2017

Danilo Fliser

series ordinal

3

1 reference

21 August 2017

1 December 2009

1 reference

Kidney International. Supplement

21 August 2017

1 reference

21 August 2017

114

1 reference

21 August 2017

S34-42

1 reference

Aortic pulse wave velocity index and mortality in end-stage renal disease

21 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

The emerging role of phosphate in vascular calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Oral active vitamin D is associated with improved survival in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Association of oral calcitriol with improved survival in nondialyzed CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Phosphorus binders and survival on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Cinacalcet suppresses calcification of the aorta and heart in uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Structural and biochemical properties of fibroblast growth factor 23.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

FGF-21 as a novel metabolic regulator

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

FGF23 is processed by proprotein convertases but not by PHEX.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Determination of the elimination half-life of fibroblast growth factor-23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Regulation of fibroblast growth factor-23 signaling by klotho

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Cellular signaling by fibroblast growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Structural basis for fibroblast growth factor receptor activation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Klotho converts canonical FGF receptor into a specific receptor for FGF23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Physiological regulation of renal sodium-dependent phosphate cotransporters

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Pathogenic role of Fgf23 in Dmp1-null mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

The role of phosphate in the secretion of parathyroid hormone in man

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

FGF-23 in patients with end-stage renal disease on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Severely reduced production of klotho in human chronic renal failure kidney.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Timing of onset of CKD-related metabolic complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Vitamin D levels and patient outcome in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

A bimodal association of vitamin D levels and vascular disease in children on dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Vitamin D levels and early mortality among incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Does FGF23 toxicity influence the outcome of chronic kidney disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Effect of dialysis dose and membrane flux in maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.405

7 January 2021

Identifiers

DOI

10.1038/KI.2009.405

1 reference

21 August 2017

1 reference

PubMed ID

19946326